CVRx Announces Key Senior Leadership Team Hires
CVRx, a commercial-stage medical device company, announced the addition of three key executives to its senior leadership team. Dr. Philip B. Adamson will join as Chief Medical Officer, Bonnie Handke as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund as Senior Vice President of Global Clinical Affairs. These new roles aim to drive the adoption of CVRx's Barostim™ therapy and expand patient access. Dr. Adamson brings nearly three decades of experience in heart failure from Abbott Laboratories, Bonnie Handke comes with extensive experience from Medtronic, and Jennifer Englund has a strong background in leading clinical strategies in the medical device industry. The new hires will focus on making Barostim therapy a standard of care for heart failure patients.
- Three senior leadership hires align with strategic goals.
- Dr. Adamson's nearly 30 years of experience in heart failure.
- Bonnie Handke's proven track record in market access strategies.
- Jennifer Englund's experience in clinical evidence generation.
- Focus on making Barostim therapy a standard of care.
- No immediate financial impact mentioned.
- Potentially high costs associated with new hires.
- Dependence on successful adoption of Barostim therapy.
- Dr. Philip B. Adamson will join as Chief Medical Officer
- Bonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics
- Jennifer E. Englund joins as Senior Vice President of Global Clinical Affairs
MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed) has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA will assume the role of Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund recently joined as Senior Vice President of Global Clinical Affairs. These roles will focus on driving the adoption of the company's Barostim™ therapy and expanding patient access.
"We are thrilled to welcome Dr. Adamson, Bonnie, and Jennifer to the CVRx leadership team. These three executives will play an important role as we seek to move our Barostim therapy towards standard of care," said Kevin Hykes, President and CEO of CVRx. "Dr. Adamson's deep expertise and relationships within the clinical community will be invaluable as we seek to drive awareness and appropriate adoption among clinicians. Bonnie's extensive experience in developing and executing market access strategies will be central in our efforts to expand patient access and secure favorable reimbursement. Jennifer's proven track record in leading successful clinical evidence generation strategies will be instrumental in further validating the efficacy of Barostim and supporting our pursuit of expanded indications.”
As Chief Medical Officer, Dr. Adamson will spearhead efforts to drive awareness and appropriate use of Barostim therapy among clinicians. He will guide comprehensive medical education, outreach and guideline integration initiatives to establish Barostim as the standard of care for patients with heart failure. Dr. Adamson joins CVRx from Abbott Laboratories, where he serves as Divisional Vice President and Chief Medical Officer of the Heart Failure division. A renowned expert in heart failure, he has nearly three decades of experience in academia as a professor and as a practicing cardiologist, during which time he authored over 150 manuscripts and book chapters. Dr. Adamson earned his MD with distinction from the University of Oklahoma College of Medicine and MSc in physiology from the University of Oklahoma. He will begin his employment at CVRx on May 23, 2024.
As Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, Bonnie Handke, RN, MBA, will lead CVRx's efforts to expand access to Barostim therapy. She is coming to CVRx from Medtronic, which she joined over 25 years ago as a Senior Manager in Neuromodulation and steadily progressed through roles of increasing responsibility, most recently serving as Vice President of Global Healthcare Economics, Policy and Reimbursement for the Cardiovascular portfolio. Handke has a proven track record of developing and executing market access strategies for numerous novel therapies, successfully navigating complex reimbursement landscapes. Handke earned an MBA from St. Thomas University, a BA from Concordia University, and an AS in Nursing from Normandale Community College. Bonnie will begin her new role on May 28, 2024.
Jennifer Englund joined CVRx as Senior Vice President of Global Clinical Affairs on May 1, 2024, overseeing the development and execution of the company's clinical evidence generation strategy, including designing and optimizing a pipeline of post-market studies. Englund brings over 25 years of experience in the medical device industry, most recently serving as Senior Vice President, Scientific Affairs at Monteris Medical, where she established a strong clinical portfolio that was pivotal in achieving reimbursement and clinical guideline status. She has also held clinical leadership roles at POPS! Diabetes Care, Mardil Medical, and Catheter Robotics. Englund holds a BS in Biology and BA in Psychology from the University of Minnesota.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
FAQ
What roles were announced in the CVRx press release on May 16, 2024?
Who is the new Chief Medical Officer of CVRx?
What is Bonnie Handke's role at CVRx?
When did Jennifer E. Englund join CVRx?
What is the focus of the new hires at CVRx?
What experience does Dr. Philip B. Adamson bring to CVRx?
What is the Barostim therapy mentioned in the CVRx press release?
